CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Abstract Background Recently, CD7-targeted CAR-T cells have shown both safety and efficacy in early-stage clinical studies. More than 95% of T-cell malignancies and 30% of acute myeloid leukemia cells express CD7, rendering CD7 CAR-T cells to become a promising candidate for the development of next-generation cellular therapy. However, since >90% of normal T cells also express CD7, the potential o…